NOGA-103

NOGA-103 is an investigational gene therapy drug being developed by Noga Therapeutics. The company specializes in lentiviral vector-based gene therapies that aim to reprogram blood stem cells to treat severe and chronic illnesses, including rare genetic diseases and neurological disorders. While specific details regarding NOGA-103's precise mechanism of action or primary indication are not publicly detailed, it is part of a pipeline that leverages advanced gene delivery platforms to potentially offer affordable, effective, and off-the-shelf solutions. Noga Therapeutics' approach involves engineering lentiviral vectors to integrate desired genes directly into hematopoietic stem cells, enabling the sustained production of therapeutic proteins.